

Integrin Alpha 7 (ITGA7) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/I31B4654780EN.html>

Date: June 2018

Pages: 26

Price: US\$ 3,500.00 (Single User License)

ID: I31B4654780EN

Abstracts

Integrin Alpha 7 (ITGA7) - Pipeline Review, H1 2018

SUMMARY

Integrin Alpha 7 (ITGA7) pipeline Target constitutes close to 9 molecules. The latest report Integrin Alpha 7 (ITGA7) - Pipeline Review, H1 2018, outlays comprehensive information on the Integrin Alpha 7 (ITGA7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Integrin Alpha 7 (ITGA7) - Alpha-7 integrin is a protein encoded by the ITGA7 gene. It induces changes in the shape and mobility of myoblasts, and facilitates their localization at laminin-rich sites of secondary fiber formation. It is involved in the maintenance of the myofibers cytoarchitecture as well as for their anchorage, viability and functional integrity.

The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 4 and 4 respectively. Report covers products from therapy areas Musculoskeletal Disorders and Genetic Disorders which include indications Muscular Dystrophy and Duchenne Muscular Dystrophy.

Furthermore, this report also reviews key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 7 (ITGA7)

The report reviews Integrin Alpha 7 (ITGA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics and enlists all their major and minor projects

The report assesses Integrin Alpha 7 (ITGA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Integrin Alpha 7 (ITGA7) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Integrin Alpha 7 (ITGA7)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Integrin Alpha 7 (ITGA7) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Integrin Alpha 7 (ITGA7) - Overview

Integrin Alpha 7 (ITGA7) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Integrin Alpha 7 (ITGA7) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Molecule Type

Integrin Alpha 7 (ITGA7) - Companies Involved in Therapeutics Development

Strykagen Corp

Integrin Alpha 7 (ITGA7) - Drug Profiles

Stryka-232 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stryka-234 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stryka-425 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stryka-516 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stryka-516s - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stryka-533 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress
Stryka-969 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stryka-978 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
StrykaPro-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Strykagen Corp, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Strykagen Corp

I would like to order

Product name: Integrin Alpha 7 (ITGA7) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/I31B4654780EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I31B4654780EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970